KLF4 and SOX9 transcription factors antagonize β-catenin and inhibit TCF-activity in cancer cells  by Sellak, Hassan et al.
Biochimica et Biophysica Acta 1823 (2012) 1666–1675
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrKLF4 and SOX9 transcription factors antagonize β-catenin and inhibit TCF-activity in
cancer cells
Hassan Sellak a,⁎, Songwei Wu b, Thomas M. Lincoln a
a Department of Physiology, University of South Alabama, Mobile, AL, USA
b Center for Lung Biology and Department of Pharmacology, University of South Alabama, Mobile, AL, USA⁎ Corresponding author at: College of Medicine, Depar
of South Alabama, Medical Science Bldg., Rm. 3103, Mobi
461 1369; fax: +1 251 460 6386.
E-mail address: hsellak@usouthal.edu (H. Sellak).
0167-4889/$ – see front matter. Published by Elsevier B
doi:10.1016/j.bbamcr.2012.06.027a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 May 2012
Received in revised form 20 June 2012
Accepted 21 June 2012
Available online 2 July 2012
Keywords:
β-catenin
KLF4
Sox9
Cancer
Wnt signaling
T-cell factorThe transcriptional activator β-catenin is a keymediator of the canonicalWnt signaling pathway. β-catenin itself
does not bind DNA but functions via interaction with T-cell factor (TCF)/lymphoid-enhancing factor (LEF) tran-
scription factors. Thus, in the case of activeWnt signaling,β-catenin, in cooperationwith TCF/LEF proteins family,
activates the expression of a wide variety of genes. To date, the list of established β-catenin interacting targets is
far from complete. In this study, we aimed to establish the interaction between β-catenin and transcription fac-
tors that might affect TCF activity. We took advantage of EMSA, using TCF as a probe, to screen oligonucleotides
known to bind speciﬁc transcription factors that might dislodge or antagonize β-catenin/TCF binding.We found
that Sox9 and KLF4 antagonizeβ-catenin/TCF binding inHEK293, A549, SW480, and T47D cells. This inhibition of
TCF binding was concentration-dependent and correlated to the in vitro TCF-luciferase functional assays. Over-
expression of Sox9 and KLF4 transcription factors in cancer cells shows a concentration-dependent reduction
of TCF-luciferase as well as the TCF-binding activities. In addition, we demonstrated that both Sox9 and KLF4 in-
teract with β-catenin in an immunoprecipitation assay and reduce its binding to TCF4. Together, these results
demonstrate that Sox9 and KLF4 transcription factors antagonize β-catenin/TCF in cancer cells.
Published by Elsevier B.V.1. Introduction
Canonical Wnt/β-catenin signaling pathway is involved in control-
ling a wide range of developmental processes, including tissue pattern-
ing, cell fate, and cell proliferation [1,2]. Free β-catenin translocates to
the nucleus, binds TCF proteins, and activates a multitude of genes
[2,3]. The precise mechanism by which β-catenin/TCF activity is regu-
lated is under extensive investigation but not yet solved. Although
this mechanism has not been fully elucidated, there is evidence to sup-
port various possibilities such as protein–protein interaction, recruit-
ment of co-activators or co-repressors by β-catenin and TCF [4], as
well as β-catenin nuclear translocation [5].
The Krüppel-like factor (KLFs) family of gene regulatory proteins are
transcription factors implicated in the regulation of a wide range of cel-
lular processes, including proliferation, apoptosis, differentiation, inﬂam-
mation, migration, and tumor formation [6–8]. Since cancers display
uncontrolled cell growth, KLF4 is thought to play a key role in cancer pro-
gression and development [9,10]. KLF4 is proven to induce growth arrest
[6,11] and to possess tumor suppressive activity [12,13]. This tumor sup-
pressor activity of KLF4 is supported by in vivo evidence in which mice
heterozygous for KLF4 manifest increased tumor burden when bred totment of Physiology, University
le, AL 36688, USA. Tel.: +1 251
.V.the APCMin mice that are genetically predisposed to intestinal adenoma
formation [14]. KLF4 expression is shown to be downregulated in a num-
ber of cancers [13,15,16]. However, its role in cancer is not fully conclu-
sive as it is also identiﬁed to act as an oncogene in some cancers and
speciﬁcally breast cancer [17,18]. It is postulated that a cross talk be-
tweenKLF4 andβ-catenin regulates intestinal homeostasis [19]. Further-
more, it is deduced that KLF4 binds the transcriptional activation domain
of β-catenin and inhibits its transcription [19]. A recent study showed
that lower levels of KLF4 expression in the proliferative compartment
of the intestinal epithelium are regulated by the transcription factors
TCF4 and Sox9, an effector and a target, respectively, of Wnt/β-catenin
[20,21]. This substantiates the ﬁnding that reduced levels of KLF4
tumor suppressor activity in colon tumors may be driven by elevated
Wnt/β-catenin signaling. In addition, Yori et al. demonstrated that forced
expression of KLF4 in themicemodel inhibits primary tumor growth and
metastasis of breast cancer cells [22]. These data support the role of KLF4
as a tumor and metastasis suppressor in the breast.
The SOX family of transcription factors has emerged as modulators
of canonical Wnt/β-catenin signaling in diverse development and dis-
ease contexts [23] where they act as both agonists or antagonists of
β-catenin/TCF activity [24]. Although Sox9 is required for differentia-
tion of variety of tissues, its dysregulation results in intestine, lung, pan-
creatic, ovarian, and prostate cancer [25]. Sox9 is overexpressed in
tumors from many origins [26], and from most data its anti-cancer ef-
fect was reported [27] in addition of decreasing Wnt signaling activity
[28,29]. β-catenin has also been shown to interact with SOX-families
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controlsWnt signaling in chondrocytes [30]. Conﬂicting results subsist re-
garding the mechanism by which Sox9 leads to β-catenin/TCF inactiva-
tion. While the association of Sox9 to the β-catenin destruction complex
promotes β-catenin degradation in the nucleus [31], another study
found that Sox9 inhibits β-catenin/TCF activity without affecting
β-catenin level [19]. As Sox and TCF proteins bind similar DNA sequences
[32,33], Sox proteins might also suppress Wnt-induced transcription by
competing with TCF for the same promoter sites. However, in vitro DNA
binding studies with optimized Sox and TCF DNA-binding sites argue
against this model and suggest that Sox proteins bind an optimized TCF
consensus sequence very poorly, if at all, and vice versa [23]. Furthermore,
severalmembers of the Sox family, including Sox17, Sox3, Sox7, and Sox9,
have been implicated in repressingβ-catenin activity bymechanisms that
are not yet understood [34–37]. These studies along with others suggest
that Sox9 and KLF4 proteins can cooperate with or antagonize
β-catenin/TCF function depending on the context. In this study, we
aimed to identify transcription factors that might interact with
β-catenin to prevent its binding to TCF. This was achieved by visualizing
protein-DNA binding using electrophoretic mobility shift assay and vali-
dating the obtained data with functional TCF-luciferase experiments.
We found that among many transcription factors, Sox9 and KLF4 were
the most potent in inhibiting β-catenin/TCF binding and activity.2. Material and methods
2.1. Cell culture
Colon cancer cells (SW480, SW620, LoVo), breast cancer cells
(T47D, MCF-9, Hs578T), and lung cancer cells (A549, H249, H460)
were obtained from ATCC cell line collection (Manassas, VA). Cells
were cultured in the same medium (DMEM) with 10% FBS to avoid
any growth variability. HEK293 cells were purchased from ATCCA B
Fig. 1. Panel A. Competition of TCF-binding with different consensus oligonucleotide sequence
performed as described in theMaterial andmethods. Excess of unlabeled oligonucleotideswas p
probe. After 30 min incubation in the presence of TCF-radiolabeled probe, proteinswere resolve
NF-κB, 7: NFAT, 8: TFIID, 9: AP1, 10: KLF4, 11: SRF, 12: OCT1, 13: AP2, 14: SREB; 15, GATA. Pan
pendent. Nuclear extracts prepared from SW480 colon cancer cells were incubatedwith increas
and incubation was carried for another 30 min before resolving proteins on native polyacrylam
resentative of three independent experiments.and cultured in DMEM 10%. Cell passaging was performed when
they reached 80% conﬂuence and the medium is changed every
three days.2.2. Electrophoretic mobility shift assay (EMSA)
The oligonucleotides Sp1, AP1, NF-kB, CREB, TFIID, and OCT1
were purchased from Promega (Madison, WI) or synthesized
from MWG Biotech (High Point, NC) (TCF, SRF, Sox9, KLF4, SREB,
AP2, GATA, and NFAT). Nuclear extracts were prepared from cells
using a nuclear and cytoplasmic extraction reagent (NE-PER, Ther-
mo) following the protocol provided by the manufacturer. Oligo-
nucleotides were dimerized and gel puriﬁed. Next, 10 μg of
nuclear extract in 10 μl of binding buffer was mixed with 2 μg of
poly[dI–dC] and 1 μg of BSA to a ﬁnal volume of 19 μl. After
30 min incubation on ice, with or without excess of cold probes,
1 μl (50,000 cpm) of [γ-32P]ATP (Perkin Elmer, Norwalk, CT)
end-labeled double-stranded consensus oligonucleotides (either
TCF, Sox9, or KLF4) was added to each reaction and incubated on
ice for an additional 30 min. The reaction products were separated
on a 6% native polyacrylamide 0.5% Tris–borate–EDTA gel. Gels
were then dried and exposed to autoradiographic ﬁlm. The se-
quences [5′→3′] of the oligonucleotides used in the EMSA are:
TCF [GGTAAGATCAAAGGGG]; Sox9 [GGGAGAGAACAATGGGTGCC
CTAC ]; KLF4 [ATGCAGGAGAAAGAAGGGCGTAGTATCTACTAG]; GA
TA [CACTTGATAACAGAAAGTGATAACTCT]; NF-κB [AGTTGAGGGGA
CTTTCCCAGGC]; AP1 [CGCTTGATGAGTCAGCCGGAA]; CREB [AGA
GATTGCCTGACGTCAGAGAGCTAG]; NFAT [CGCCCAAAGAGGAAAAT
TTGTTTCATA]; Sp1 [ATTCGATCGGGGCGGGGCGAG]; AP2 [GATCGA
ACTGACCGCCCGCGGCCCGT]; OCT-1 [TGTCGA ATGCAA ATCACTAG
A A]; TFIID [GCAGAGCATATA AGGTGAGGTAGGA]; SRF [GGATGTC
CATATTAGGACATCT]; and SREB [GCGTAGCTCTTTCTCCCCCCACCCA
CCAACCT].s. Nuclear extract proteins were prepared from SW480 colon cancer cells and EMSA were
reincubatedwith nuclear protein extracts (10 μg) 30 min before adding TCF-radiolabeled
d on native polyacrylamide gel. 0: free probe, 1: control, 2: TCF, 3: CREB, 4: Sp1, 5: Sox9, 6:
el B. The reduction of TCF binding by Sox9 and KLF4 oligonucleotides is concentration de-
ing amounts of TCF, Sox9, and KLF4 cold oligonucleotides for 30 min. TCF probewas added
ide gel. C: control, 1: 10-, 2: 25-, 3: 50-, 4: 100-fold excess in cold probes. Figures are rep-
A B
Fig. 2. TCF does not abolish Sox9 and KLF4 binding. Nuclear protein extracts were prepared from SW480 colon cancer cells and EMSA was performed as described in the Material
and methods. Oligonucleotides at increasing concentration (10-, 25-, 50-, or 100-fold excess) were incubated with nuclear extract proteins (10 μg) for 30 min before adding either
radiolabeled KLF4 (panel A) or Sox9 (panel B) probes and resolving proteins on native polyacrylamide gel. Figures are representative of three independent experiments.
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To evaluate the TCF/LEF transcriptional activity, we used a pair of
luciferase reporter constructs, TOPFlash and FOPFlash (Upstate Bio-
technology). TOPFlash contains three copies of the TCF/LEF binding
site [AAGATCAAAGGGGGT] upstream of the thymidine kinase mini-
mal promoter, and FOPFlash contains a mutated TCF/LEF binding
site [AAGGCCAAAGGGGGT]. The underlined nucleotides were mutat-Fig. 3. Sox9 and KLF4 oligonucleotides abolish TCF-binding activity in cancer cells. Nuclear p
says were performed as described in the Material and methods. Excess of TCF (lane 2), Sox9
teins (10 μg) for 30 min. After adding TCF-radiolabeled probe and additional 30 min incubat
each cell represents a Western blot for β-catenin expression. The ﬁgure is representative oed in FOPFlash-luciferase reporter construct. Cells were transiently
transfected with 250 ng of each luciferase reporter using Fugene HD
transfection reagent (Roche, Indianapolis, IN), as instructed by the
supplier. In cotransfection experiments, various concentrations of dif-
ferent expression vectors were combined with 250 ng of TOPFlash or
FOPFlash in the presence of Fugene HD. Luciferase activities were mea-
sured 48 h post-transfection using luminometer TD20/20 (Promega).
The results are expressed as a ratio of TOPFlash:FOPFlash normalizedrotein extracts (10 μg) were prepared from the indicated cancer cells and gel shift as-
(lane 3), or KLF4 (lane 4) oligonucleotides was preincubated with nuclear extract pro-
ion, proteins were resolved on native polyacrylamide gel. The square under the name of
f three independent experiments.
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fection efﬁciency. Expression vectors: β-catenin was from Addgene;
Sox9 (sc321884) and KLF4 (sc123501) were from Origene (Rockville,
MD).
2.4. Western blot analysis
Western blots were performed to verify the overexpression of pro-
teins in control and transfected cells. Total protein extracts (60 μg) were
separatedon10%SDS-PAGEand transferred tonitrocellulosemembranes.
The blots were probed with anti-Sox9 (Santa-Cruz Biotechnologies, CA),
anti-KLF4 (Abcam, Cambridge, MA), anti-β-catenin (Millipore, Bedford,
MA), and anti-β-actin (Santa-Cruz) antibodies. The signal was detected
by enhanced chemiluminescence (Pierce, Rockford, IL).
2.5. Immunoprecipitation
HEK293 cells were transiently transfected for 48 h to over-
express β-catenin/Sox9 or β-catenin/KLF4. Cells were washed
twice with ice-cold PBS and extracted with RIPA buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.5 mM
sodium orthovanadate) containing a protease inhibitor cocktail
(Pierce). Protein concentrations were determined and 200 μg of
protein was incubated over night under rotation at 4 °C withA
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Fig. 4. Overexpression of Sox9 or KLF4 inhibits both TCF-binding and activity. Panel A, SW4
TCF-luciferase expression vectors. Forty-eight hours later, cells were lysed and luciferase ass
tive of three independent experiments performed in triplicates. **pb0.01. Panel B, in a para
48 h later nuclear extract proteins (10 μg) were prepared and incubated with TCF-radiolabe
2: Sox9; 3: KLF4 expression vectors. The ﬁgure is representative of three independent expeantibodies (anti-KLF4 from Abcam or anti-Sox9 from Santa-Cruz)
bound to protein G-agarose following the protocol provided by
the company (Santa-Cruz). Immunoprecipitates were washed
with RIPA buffer for ﬁve times while transferring to new tubes
each time. The proteins were solubilized with reducing sample
buffer and were analyzed for β-catenin expression by SDS-PAGE
and immunoblotting. Immunoblots were developed using en-
hanced chemiluminescence (Pierce).
To demonstrate that Sox9 and KLF4 reduce the interaction between
β-catenin and TCF-4, SW480 cells were transfected with different
amounts of Sox9 and KLF4 (0, 0.5, or 1 μg) expression vectors for 48 h.
Nuclear extracts proteins were prepared and immunoprecipitation was
performed as described above using anti-TCF4 antibody (Santa-Cruz Bio-
technologies) followed by Western blot using anti-β-catenin antibody.
Histone H1 was used as protein loading control and detected using
anti-Histone H1 antibody (Santa-Cruz Biotechnologies).2.6. Statistical analysis
All luciferase assays were performed in at least triplicates and
repeated a minimum of 3 times. Results are expressed as mean±
standard deviation (SD). Signiﬁcant differences between means
compared to the control were determined using Student's t-test as
*pb0.05 and **pb0.01.4
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Fig. 5. Overexpression of Sox9 or KLF4 concentration dependently inhibits TCF-luciferase activity. HEK293, SW480, A549, and T47D cells were co-transfectedwith either Sox9/TCF-luciferase
or KLF4/TCF-luciferase constructs at concentrations ranging from0 to 200 ng. Forty eight hours later, luciferase assayswere performed as described in theMaterial andmethods. Theﬁgure is
representative of four independent experiments performed in triplicates. *pb0.05, **pb0.01.
A B
Fig. 6. Sox9 and KLF4 oligonucleotides decreased TCF-binding activity in HEK293 cells
overexpressing β-catenin. Nuclear extract proteins were prepared from non-transfected
HEK293 (panel A) or HEK293 cells transfected with 1 μg of β-catenin expression vector
(panel B) and incubated with excess of TCF, Sox9, or KLF4 oligonucleotides for 30 min.
TCF-radiolabeled probe was added and incubated for another 30 min before resolving
proteins on native polyacrylamide gel. The ﬁgure is representative of at least three inde-
pendent experiments.
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3.1. Sox9 and KLF4 oligonucleotides antagonize β-catenin binding to TCF
In an attempt to determine which transcription factor might dis-
lodge β-catenin binding to a synthetic TCF probe, EMSAwas performed.
Excess of different oligonucleotideswas pre-incubatedwith nuclear ex-
tracts, prepared from SW480 colon cancer cells, 30 min before adding
γ-32P-labeled TCF probe. The sequences of consensus oligonucleotides
known to bind speciﬁc transcription factors are reported in EMSA sec-
tion (see Material and methods). The Sox9 consensus sequence was
previously described [36] and used in this study. Fig. 1A shows the re-
sults of a representative gel shift assay to analyze β-catenin/TCF com-
plex formation. The upper band corresponds to β-catenin/TCF shift
and the lower band represents TCF binding (see arrows). We can see
that TCF-binding decreased by excess of TCF (lane 2), Sox9 (lane 5),
and KLF4 (lane 10) oligonucleotides. In addition to these three oligonu-
cleotides, the sequence recognizing serum response factor SRF was also
shown to inhibit TCF-binding (lane 11) but was not considered in this
study. Fig. 1B represents an EMSA competition experiment using TCF
as a probe and nuclear extract proteins harvested from SW480 cells.
When excess of unlabeled Tcf oligonucleotide was used, all shifted
bands were erased including β-catenin (upper band). Also shown in
Fig. 1B the reduction of TCF binding by Sox9 and KLF4 oligonucleotides
was concentration-dependent. These results suggest that the following
possibilitiesmight occur in this in vitro binding assay: ﬁrst, Sox9 or KLF4
oligonucleotides, through binding to their respective transcription fac-
tors, might bind to TCF DNA and therefore oppose TCF protein binding;
second, these oligonucleotides might compete with TCF proteins for
β-catenin binding. In this situation, these oligonucleotides, through
1671H. Sellak et al. / Biochimica et Biophysica Acta 1823 (2012) 1666–1675their respective transcription factors, interact with β-catenin and op-
pose its binding to TCF proteins; third, these oligonucleotides, through
binding their respective transcription factors, might recognize both
β-catenin and TCF protein and ultimately inhibit TCF-binding activity.
To rule out which possibility is occurring in this model, we tested
whether TCF oligonucleotide could compete with either Sox9- or
KLF4-radiolabeled probes.
3.2. Sox9 and KLF4 antagonize TCF binding but TCF does not abolish Sox9
or KLF4 binding
The results in Fig. 2A revealed that when KLF4 was used as a
radiolabeled probe, excess of TCF oligonucleotide could not reduce
KLF4 binding. However, a slight inhibition was detected when Sox9 ol-
igonucleotide was used at a higher concentration (100-fold). Similarly,
when Sox9 was used as a probe (Fig. 2B), the excess of either TCF or
KLF4 oligonucleotides did not affect Sox9 binding activity. These results
demonstrate that TCF oligonucleotide does not compete with Sox9 or
KLF4 probes for the binding of either Sox9 or KLF4 transcription factors.
This result eliminates theﬁrst possibility described above. However, the
mechanism by which Sox9 and KLF4 reduce TCF-binding activity is not
yet solved. To conﬁrmwhether Sox9 and KLF4 inhibition of TCF-binding
activity was not mediated through competition between Sox9 or KLF4
and TCF proteins for binding to TCF DNA-sites, we examined the bind-
ing speciﬁcity of Sox9, KLF4 aswell as TCF by EMSA. Gel bands obtained
with TCF consensus sequence were not shifted when using antibodies
directed against Sox9 or KLF4. These results suggest that neither Sox9
nor KLF4 bind to the TCF-complex (data not shown).
3.3. Sox9 and KLF4 inhibition of TCF-binding activity occurs in most test-
ed cancer cells
To verifywhether the inhibition of TCF binding by Sox9 andKLF4 ex-
cess oligonucleotides was speciﬁc to SW480 colon cancer cells, nuclear
extracts were prepared from different cancer cell lines and EMSA was
performed as described in the Material and methods. Results in Fig. 3
show that the TCF band (bottom arrow) is retarded in almost all the nu-
clear extracts prepared from different cells but with different intensities
depending on the amount of TCF proteins within each cell. The shifted
band corresponds to β-catenin (top arrow) as assessed by anti-
β-catenin antibody. Similarly, the intensity of the shifted β-catenin/TCF
intensity varies from cells to cell depending on the nuclear amount of
this protein. We can see also that higher binding activities were obtained
whennuclear extractswere prepared fromSW620 and SW480 colon can-
cer cells. This strong TCF-binding activity was correlated to higher
TCF-luciferase activity in these two cells (result not shown). As also
shown in Fig. 3, excess of TCF (lane 1), Sox9 (lane 2), or KLF4 (lane 3)
oligonucleotides inhibited TCF-binding in tested cancer cells. It is notice-
able that both SW480 and SW620 shifted a band corresponding to
β-catenin compared to all nuclear extracts prepared from other cells.
However, longer exposure of the ﬁlm showed that β-catenin was shifted
in most cells (data not shown). The square under the name of each cell
represents a Western blot for β-catenin expression showing that, as
expected, cells express variable amounts of β-catenin. These results dem-
onstrate that Sox9 and KLF4 oligonucleotides decrease TCF-binding in
tested cancer cell lines, and suggest the plausible involvement of a com-
mon mechanism governing the interaction of these transcription factors
with the β-catenin/TCF complex. However, these results do not exclude
that Sox9 or KLF4might bind bothβ-catenin and TCF proteins, preventing
them from binding to TCF probe.
3.4. Overexpression of Sox9 and KLF4 inhibits both TCF-binding and lucif-
erase activity
In an attempt to demonstrate whether Sox9 or KLF4 expression
vectors inhibit TCF-binding activity by interacting with β-catenin, wecotransfected Sox9 or KLF4 expressing vectorswith TCF-luciferase report-
er constructs (TOPFlash and FOPFlash) in SW480, A549, and TD47 cancer
cells and performed TCF-binding (EMSA) as well as TCF-luciferase assays.
Results in Fig. 4A show that Sox9 or KLF4 cotransfection with TCF-
luciferase reporter construct reduced TCF activity in SW480, A549, and
T47D cells. This decrease in TCF-luciferase activity was concentration-
dependent as shown in Fig. 5. In parallel, thedecrease in TCF-luciferase ac-
tivity was accompanied with a concomitant reduction in TCF–complex
binding (see asterisk) when EMSA was performed using nuclear extracts
harvested from SW480, A549 and T47D cells and TCF as a radiolabeled
probe (Fig. 4B). Taken together, these data demonstrate a net correlation
between the inhibition of TCF-luciferase activity and the decrease in TCF-
binding following Sox9 and KLF4 transcription factors overexpression.
Since it has been previously reported that KLF4 can decrease
β-catenin mRNA and protein levels in the human colon cancer cell line
HT29 [20], we examined whether overexpression of either Sox9 or
KLF4 transcription factors inhibits TCF-activity by affecting β-catenin
protein levels. After overexpression of these transcription factors in
SW480 cells and quantifying β-catenin levels by Western blot, we did
not ﬁnd any change in β-catenin expression levels (data not shown).
These results suggest that Sox9 and KLF4 inhibit β-catenin bindingwith-
out affecting its expression level in SW480 cells.
3.5. Sox9 and KLF4 oligonucleotides decrease TCF-binding activity in
HEK293 cells overexpressing β-catenin
To address whether Sox9 and KLF4 oligonucleotides dislodge
β-catenin binding to TCF complex, HEK293 cells were transiently
cotransfected with β-catenin expression vector and TCF-luciferase re-
porter construct. Nuclear extracts were harvested 48 h post transfec-
tion, and TCF-binding assays were performed as described in the
Material and methods. As shown in Fig. 6A, when β-catenin was not
overexpressed (panel A), only a reduction in TCF-binding complex
was obtained since no β-catenin shift was detected, even though
these cells contain a detectable amount of β-catenin and express
high TCF-luciferase activity, similar to SW480 and SW620 colon can-
cer cells (data not shown). However, when HEK293 cells were over-
expressing β-catenin (Fig. 6B), β-catenin is retarded on the gel
(lane 1, see arrow), and its binding was eliminated by excess of TCF
(lane 2, 3), and reduced, at different intensities, by Sox9 (lane 5),
and KLF4 (lane 7) oligonucleotides. These results suggest that KLF4
and Sox9 inhibit β-catenin binding to TCF proteins. However, wheth-
er KLF4 and Sox9 transcription factors could antagonize β-catenin
binding in cancer cells is not yet solved.
3.6. Overexpression of Sox9 and KLF4 dislodge β-catenin binding to TCF
To demonstrate whether Sox9 and KLF4 transcription factors affect
β-catenin binding, we performed EMSA using nuclear extracts prepared
from HEK293 or SW480 cells overexpressing Sox9, KLF4, β-catenin,
β-catenin/Sox9,β-catenin/KLF4, orβ-catenin/Sox9/KLF4 expression vec-
tors. Results in Fig. 7A show that a band corresponding to β-catenin was
shifted (lane 4) in nuclear extracts from HEK293 cells overexpressing
β-catenin (panel A). This band was reduced following cotransfection of
β-catenin with either Sox9 (lane 5), KLF4 (lane 6) or both Sox9/KLF4
(lane 7) expression vectors. Using nuclear extract proteins prepared
from SW480 (Fig. 7B), the binding was reduced by Sox9 (lane 5), KLF4
(lanes 6), and a combination of both (lane 7) compared to the control
(lane 1). Results in Fig. 7C show a representative Western blot for
HEK293 and SW480 cells overexpressing Sox9, KLF4, or β-catenin.
These results demonstrate that Sox9 and KLF4 transcription factors pre-
vent β-catenin from binding to TCF proteins. This inhibition is correlated
to the decrease in TCF-luciferase activity shown in Fig. 4A. Taken togeth-
er, these data suggest that Sox9 and KLF4 transcription factors bind to
β-catenin and prevent its interaction with TCF, resulting in inhibition of
both TCF-binding and TCF-luciferase activities.
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To demonstrate whether Sox9 or KLF4 transcription factors inter-
act with β-catenin and ultimately reduce its binding to TCF proteins,
HEK293 cells were transiently cotransfected with either Sox9/
β-catenin or KLF4/β-catenin expression vectors. Immunoprecipita-
tion was performed with anti-Sox9 or anti-KLF4 antibodies respec-
tively. The blotting was performed with anti-β-catenin antibody.
Fig. 7D and E shows that Sox9 and KLF4 formed a complex with
β-catenin as predicted from EMSA studies. In lane 2 (bottom), results
show an interaction between β-catenin and Sox9 or KLF4.
3.8. Sox9 and KLF4 inhibit the interaction of β-catenin with TCF4
We observed that Sox9 and KLF4 transcription factors reduced
β-catenin/TCF binding (EMSA), inhibited TCF-luciferase activity (lu-
ciferase assays), and both interacted with β-catenin (immunoprecip-
itation). To demonstrate that Sox9 and KLF4 are implicated in
reducing β-catenin interaction with TCF proteins, SW480 cells were
transfected with these expression vectors (Sox9, KLF4), and immuno-
precipitation was performed using anti-TCF4 antibody followed by
immunoblot using anti-β-catenin antibody. Results in Fig. 7F show
that overexpression of Sox9 (2, 3) and KLF4 (2, 3) in SW480 cells con-
centration dependently reduced the amount of β-catenin that immu-
noprecipitates with TCF4 compared to the control (1). These results
demonstrate that Sox9 and KLF4 inhibit the interaction between
β-catenin and TCF4.
4. Discussion
β-catenin interacts with a multitude of transcription factors
that can act as a transcriptional activator, oncogene, or tumor sup-
pressor depending on the context (cell context, expression pattern
of other genes, or chromatin environment of individual cell) [38].
In most cancer cells, β-catenin, because of mutations occurring in
the interacting partners, escapes the scaffolding complex where it
is neutralized, and is therefore free to translocate to the nucleus
where it abnormally activates TCF-related genes and compromises
normal cell function [39,40]. The aim of this study was to determine
which transcription factor(s) might prevent β-catenin from binding to
its nuclear target, TCF proteins. For this purpose, we utilized an in vitro
TCF-binding assay (EMSA) completed by a functional TCF-luciferase
assay. Among the oligonucleotides screened, consensus sequences
binding both Sox9 and KLF4 were revealed to be good candidates for
inhibiting TCF-binding activity. Furthermore, these transcription factors
reduced both β-catenin/TCF interaction as well as TCF-luciferase activi-
ty. Moreover, this inhibition did not result from competition between
TCF and Sox9 or KLF4 DNA-binding sites. The failure of TCF oligonucle-
otide to inhibit Sox9 or KLF4 binding demonstrates that Sox9 and KLF4
transcription factors do not recognize and bind TCFDNA sequence, even
though Sox9 binding sequence was reported to be related to TCF
DNA-binding family [32,37]. Sox9 or KLF4 transcription factor over-
expression in HEK293 cells induced a marked decrease in β-catenin/
TCF-dependent activity of the synthetic TOPFlash luciferase sequence
as well as a reduction of TCF-binding. In addition, Sox9 and KLF4Fig. 7. Panels A and B. Overexpression of KLF4 and Sox9 decreased β-catenin binding to TCF. HEK
β-catenin (lane 4), β-catenin/Sox9 (lane 5), β-catenin/KLF4 (lane 6), or β-catenin/Sox9/KLF4 (lan
fection and gel shift assayswere performed as described in theMaterial andmethods using TCF as
expression (2) of Sox9, KLF4, and β-catenin in HEK283 and SW480 cells compared to non-trans
transiently cotransfected (2) for 48 h with Sox9, β-catenin, or KLF4 expression vectors (1 μg eac
(Panel E) antibodies. After running the precipitate on 10% SDS-PAGE gel and transfer, nitrocellulo
the interaction of β-catenin with TCF4. SW480 cells were transfected with Sox9 or KLF4 expressio
pared asmentioned in theMaterial andmethods, Immunoprecipitationwas performedusing anti-T
in Fig. 7F show that overexpression of Sox9 or KLF4 in SW480 results in a decrease of the amount o
proteins using anti-Histone H1 antibody (Santa Cruz). The ﬁgure is representative of three indepereduced the amount of β-catenin interacting with TCF proteins. These
lines of evidence strongly suggest the existence of a negative functional
interaction between β-catenin and Sox9 or KLF4 transcription factors
and support previous reports [30].
The inconsistency in and discrepancy among KLF4 reports may
reﬂect the pleiotropic functions of this transcription factor as well
as the complexity of its contribution as a tumor suppressor [12] or
oncogene [4,17,41]. It has been suggested that KLF4 modulation of
β-catenin/TCF4 signaling may be context-dependent [42–44]. Our
study shows that the reduction of TCF binding by Sox9 and KLF4
overexpression occurs in almost all tested cancer cells. Concomitant-
ly, a reduction in TCF-luciferase activity was observed in analyzed
cells. These results support the possibility that Sox9 and KLF4 tran-
scription factors might have a common mechanism of action in all
cancer cells. Since it was demonstrated, using GST-pull down assays
and immunoprecipitation, that KLF4 binds β-catenin as well as TCF4
[4], our observations support these results and suggest that Sox9 and
KLF4 transcription factors might interact with TCF proteins pre-
venting them from binding TCF consensus sequence. In addition, it
is possible that Sox9 and KLF4 perform different interactions to sup-
press β-catenin signaling.
Sox9 is deﬁned as a tumor suppressor [26,27,45] or oncogene [46–48]
depending on cell context and cancer type. Its effect was demonstrated
to be both β-catenin-dependent and -independent [26,27,45]. However,
the precisemechanismbywhich Sox proteins regulateβ-catenin/TCF ac-
tivity is not completely resolved, and few studies suggest the involve-
ment of different mechanisms including protein–protein interaction,
the binding of Sox factors to TCF-target gene promoters, the recruitment
of co-repressors or co-activators, and the regulation of protein stability
[30]. A negative interaction between Sox9 and β-catenin has been previ-
ously documented during chondrocyte differentiation in which dimer-
ization of Sox9 and β-catenin leads to the mutual degradation of both
proteins [30]. In addition, the existence of an antagonism between
Sox9 and β-catenin has been reported [49]. Thus, it is likely that Sox9
binds to β-catenin and excludes TCF proteins from interacting with it.
This inhibitory model of Sox9 is a feature common to KLF4 as well.
They both interact with β-catenin and prevent it from binding to TCF.
However, it is not excluded that Sox9 and KLF4 bind to TCF proteins
and prevent them from binding to TCF DNA sequence as well as to
β-catenin.
Sox9 and KLF4 could suppress β-catenin/TCF activity by mediat-
ing degradation of either β-catenin or TCF proteins. However, fol-
lowing our in vitro cotransfection experiments, neither Sox9 nor
KLF4 could cause β-catenin degradation, supporting the observa-
tion of Zhang et al. [19] where KLF4 reduces TCF-activity but does
not affect neither wild type nor mutated β-catenin levels. This pos-
sibility does not occur in our model contrary to what was previous-
ly reported [18,29,31] and where KLF4 downregulates the level of
β-catenin by direct binding and inhibition of its transcriptional ac-
tivation domain. In addition, a recent report shows that the de-
crease in β-catenin/TCF transcriptional activity was not due to
reduced interaction between β-catenin and TCF4 but was associat-
ed with an increased interaction between β-catenin and KLF4.
As Sox and TCF proteins bind similar DNA sequences, Sox pro-
teins might also suppress Wnt-induced transcription by competing293 (panel A) or SW480 (panel B) cells were transfected with Sox9 (lane 2), KLF4 (lane 3),
e 7) expression vectors (1 μg each). Nuclear extract proteins were prepared 48 h post trans-
a radiolabeled probe. Lane 1 corresponds to control. Panel C.Western blot showing the over-
fected cells (1). Panels D and E. Sox9 and KLF4 interact with β-catenin. HEK293 cells were
h). Immunoprecipitation (IP) was performed 48 h later with either Sox9 (Panel D) or KLF4
se membranes were analyzed with anti-β-catenin antibody. Panel F. Sox9 and KLF4 reduce
n vectors at different amounts (1: 0 μg, 2: 1 μg, 3: 2 μg) for 48 h. Nuclear extracts were pre-
CF4 antibody (Santa-Cruz) followedwith immunoblot using anti-β-catenin antibody. Results
f β-catenin interactingwith TCF. Histone H1was used as a loading control for nuclear extract
ndent experiments.
1674 H. Sellak et al. / Biochimica et Biophysica Acta 1823 (2012) 1666–1675with TCF for the same promoter sites. Our in vitro gel shift assays
showed that Sox9 could inhibit TCF binding but TCF did not affect
Sox9 or KLF4 binding activities. In addition, in vitro DNA-binding
studies with optimized Sox and TCF DNA-binding sites argue
against this model, and conclude that Sox proteins bind very poor-
ly, if at all, to an optimized TCF consensus sequence and vice versa
[33,35]. Subsequently, many other Sox proteins from a variety of
species have been shown to repress β-catenin stimulated TOPFlash
transcription in tissue culture as well as complexing β-catenin
[19,24,30,34,35].
In conclusion, our results demonstrate that Sox9 and KLF4 are
binding to β-catenin and reducing its interaction with TCF proteins.
As a consequence, these transcription factors inhibit TCF activity
and ultimately TCF-dependent genes activation. Given the critical
role of β-catenin in mediating Wnt signaling as well as in the devel-
opment of cancer, the identiﬁcation of inhibiting or neutralizing part-
ners will lead for a novel therapy for cancer.
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